Clinical Transition of CRISPR Gene Therapies Requires Multidisciplinary Non-Clinical Safety Framework

New research highlights the critical non-clinical safety assessments needed for CRISPR gene therapies, focusing on genotoxicity and immune risks.

By: AXL Media

Published: Apr 11, 2026, 4:03 AM EDT

Source: Information for this report was sourced from Compuscript Ltd

Prioritizing Safety in the Era of Precision Genome Editing

The rapid progression of CRISPR/Cas9 technology has transformed the landscape of cellular and gene therapy, offering the potential to correct or regulate disease-causing genes with unprecedented precision. However, as these innovations move into clinical phases, researchers from the Cell and Gene Therapy Catapult and Guy’s Hospital in the United Kingdom warn that non-clinical safety assessments must keep pace. A comprehensive review indicates that ensuring patient safety requires a shift from simple proof-of-concept studies to robust, multidisciplinary evaluation programs. These programs are designed to identify potential risks before human exposure, serving as the foundational requirement for responsible therapeutic development.

Regulatory Alignment and Risk Based Study Design

Current safety evaluations are increasingly aligned with a risk-based approach favored by the FDA and EMA. This strategy mandates that non-clinical programs be specifically tailored to the gene therapy product's delivery route, the target tissue, and the intended patient demographic. Beyond basic toxicology, developers are now expected to provide detailed analyses of biodistribution and long-term persistence within the body. By following these structured regulatory guidelines, the authors suggest that the industry can create a predictable roadmap for moving genome-edited products through the pipeline while maintaining the highest possible standards for patient protection.

Mitigating Genotoxic Risks and Unintended DNA Damage

Central to the safety discussion is the risk of genotoxicity caused by double-strand DNA breaks. When CRISPR induces these breaks, the cell’s internal repair mechanisms, such as non-homologous end joining, can accidentally introduce unintended deletions, insertions, or chromosomal rearrangements. There is also a significant concern regarding p53-mediated DNA damage responses, which could inadvertently favor the survival of oncogenic clones. To counter these risks, the review highlights the emergence of high-fidelity Cas variants, base editing, and prime editing. These newer technologies aim to minimize off-target activity and avoid the formation of double-strand breaks entirely, thereby reducing the likelihood of permanent genetic errors.